Advanced

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

Borrebaeck, Carl A K LU ; Malmborg, Ann-Christin LU and Ohlin, Mats LU (1993) In Immunology Today 14(10). p.477-479
Abstract

Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life. © 1993.

Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
in
Immunology Today
volume
14
issue
10
pages
3 pages
publisher
Elsevier
external identifiers
  • Scopus:0027485672
ISSN
0167-5699
DOI
10.1016/0167-5699(93)90259-N
language
English
LU publication?
yes
id
39816fd2-df09-4b86-bc02-a4e8bda83eff
date added to LUP
2016-04-20 13:45:23
date last changed
2016-10-13 05:06:48
@misc{39816fd2-df09-4b86-bc02-a4e8bda83eff,
  abstract     = {<p>Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life. © 1993.</p>},
  author       = {Borrebaeck, Carl A K and Malmborg, Ann-Christin and Ohlin, Mats},
  issn         = {0167-5699},
  language     = {eng},
  number       = {10},
  pages        = {477--479},
  publisher    = {ARRAY(0xb339e48)},
  series       = {Immunology Today},
  title        = {Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?},
  url          = {http://dx.doi.org/10.1016/0167-5699(93)90259-N},
  volume       = {14},
  year         = {1993},
}